Adicet Bio Inc Stock Price, News & Analysis

Adicet Bio (NASDAQ: ACET) reported Q1 2025 financial results and provided key updates on its clinical programs. The company is advancing two key programs with data readouts expected in 2H/2025: ADI-001 for autoimmune diseases and ADI-270 for clear cell renal cell carcinoma (ccRCC). The Phase 1 trial for ADI-001 has expanded enrollment to include lupus nephritis and systemic lupus erythematosus patients, with FDA granting Fast Track Designations. Financial highlights show R&D expenses of $22.8M (down from $23.9M in Q1 2024), with a net loss of $28.2M ($0.31 per share). The company maintains a strong cash position of $150.4M, expected to fund operations into 2H/2026.

Adicet Bio has announced new inducement grants under Nasdaq Listing Rule 5635(c)(4). The clinical-stage biotech company, focused on developing allogeneic gamma delta T cell therapies, granted stock options to three new employees hired in April 2025.

The key details of the grants include:

• Total shares: 206,800 of common stock
• Exercise price: $0.66 per share
• Vesting schedule: 25% after one year, remaining 75% over 36 monthly installments
• Full vesting period: 4 years

These awards were granted through Adicet's 2022 Inducement Plan, which was amended in January 2023. The compensation committee approved these grants as material inducement for new employees, complying with Nasdaq regulations.

Adicet Bio (Nasdaq: ACET), a clinical stage biotech company focused on developing allogeneic gamma delta T cell therapies, has announced its upcoming participation in the 2025 Citizens JMP Life Sciences Conference.

The company's President and CEO, Chen Schor, will engage in a fireside chat at the conference, which is scheduled for May 7-8, 2025 in New York. The presentation is set for Wednesday, May 7, 2025, at 1:30 p.m. ET.

Investors and interested parties can access the live audio webcast through the Investors section of Adicet Bio's website at www.adicetbio.com. A replay of the presentation will remain available on the website for 30 days following the event.

Adicet Bio (Nasdaq: ACET), a clinical stage biotechnology company focused on allogeneic gamma delta T cell therapies, has appointed Michael Grissinger to its Board of Directors. Grissinger brings over 40 years of pharmaceutical business development and strategic transaction experience, including more than two decades at Johnson & Johnson where he served as Vice President and Head of Worldwide Pharmaceutical Licensing and Corporate Development.

During his tenure at Johnson & Johnson, Grissinger led the Immunology Therapeutic Area Business Development and Licensing Group and was a member of the Immunology R&D/Commercial leadership team. Prior to J&J, he spent 12 years at Ciba-Geigy in finance, marketing, and business development roles. He currently serves on the board of Aprea Therapeutics and three private biotech companies.

Adicet Bio (Nasdaq: ACET) has granted inducement awards to two new employees hired in March 2025. The awards consist of non-qualified stock options to purchase 38,600 shares of Adicet's common stock at an exercise price of $0.76 per share, matching the closing price on March 31, 2025.

The vesting schedule includes 25% of shares vesting after one year, with the remaining 75% vesting in 36 monthly installments. Full vesting occurs on the fourth anniversary, contingent on continued employment. These awards were granted through Adicet's 2022 Inducement Plan, approved by the compensation committee as material inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Adicet Bio (Nasdaq: ACET), a biotechnology company focused on developing allogeneic gamma delta T cell therapies, has announced its participation in the upcoming 2025 Canaccord Genuity Horizons in Oncology Virtual Conference.

The company's President and CEO, Chen Schor, will be featured in a panel discussion titled 'CAR T Approaches in the Autoimmune Space' scheduled for Monday, April 7, 2025, at 3:00 p.m. ET. This virtual conference appearance highlights Adicet's ongoing work in both autoimmune diseases and cancer treatments.

Adicet Bio (NASDAQ: ACET) reported its Q4 and full year 2024 financial results, highlighting progress in its gamma delta T cell therapy programs. The company maintains $176.3 million in cash position as of December 31, 2024, expected to fund operations into 2H 2026.

Key developments include:

• Ongoing Phase 1 trial of ADI-001 in autoimmune diseases, with preliminary lupus nephritis data expected in 1H25
• Patient enrollment expansion for ADI-001 in multiple conditions planned for 2Q25
• ADI-270 Phase 1 trial advancing in renal cell carcinoma patients
• Fast Track Designation received for ADI-001 in February 2025

Financial highlights: Q4 2024 net loss of $28.7 million ($0.32 per share), full-year 2024 net loss of $117.1 million ($1.33 per share). R&D expenses decreased to $99.3 million in 2024 from $106.0 million in 2023.

Adicet Bio (NASDAQ: ACET) announced two poster presentations for its ADI-270 therapy at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting in San Diego. The first presentation will showcase preclinical data comparing ADI-270, an armored allogeneic anti-CD70 γδ CAR T cell therapy, to conventional αβ CAR benchmarks in terms of efficacy and safety. The second presentation will detail a Phase 1/2 first-in-human study of ADI-270 in patients with relapsed or refractory clear cell renal cell carcinoma (ccRCC). The presentations are scheduled for March 12 and 13, 2025, respectively.